Radcliffe Capital Management’s Orion Biotech Opportunities Corp. Class A Ordinary Share ORIA Stock Holding History

Radcliffe Capital Management’s Portfolio ORIA Stock Details ORIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-412,096	Closed	-$4.22M	–	680
2023 Q1	$4.22M	Hold	412,096	–	–	0.26%	119
2022 Q4	$4.14M	Buy	412,096 +591	+0.1%	+$5.88K	0.13%	242
2022 Q3	$4.05M	Buy	411,505 +30	+0%	+$294	0.1%	353
2022 Q2	$4.01M	Buy	411,475 +12,103	+3%	+$118K	0.09%	368
2022 Q1	$3.89M	Hold	399,372	–	–	0.09%	369
2021 Q4	$3.9M	Sell	399,372 -628	-0.2%	-$6.17K	0.1%	301
2021 Q3	$3.91M	Buy	+400,000	New	+$3.9M	0.11%	254

Radcliffe Capital Management's ORIA Position: Q2 2023 in Review

Radcliffe Capital Management sold out of Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) in Q2 2023, closing a stake of 412,096 shares — an estimated $4.22M sold.

Radcliffe Capital Management first reported a position in ORIA in Q3 2021 and held it in 7 quarters. The position peaked at $4.22M in Q1 2023. 0 funds tracked by Wall St. Rank hold ORIA as of Q2 2023.

Radcliffe Capital Management reported no remaining Orion Biotech Opportunities Corp. Class A Ordinary Share position as of Q2 2023 after selling out during the quarter.
Radcliffe Capital Management sold 412,096 Orion Biotech Opportunities Corp. Class A Ordinary Share shares in Q2 2023, an estimated $4.22M.
Radcliffe Capital Management first reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share in Q3 2021 and held it in 7 quarters.
Radcliffe Capital Management's Orion Biotech Opportunities Corp. Class A Ordinary Share position peaked at $4.22M in Q1 2023.
0 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Class A Ordinary Share as of Q2 2023.

Based on Radcliffe Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.